---
title: "Association of Linezolid Interruption and Rechallenge With Outcomes in Rifampicin-Resistant TB,"
id: "the-lancet-global-health-21-association-of-linezolid-interruption-and-rechallenge-with-clinical-outcomes-in-patients-with-rifampicin-resistant-tuberculosis-in-south-africa-2018-22-an-observational-cohort-study"
canonical_url: "https://medichelpline.com/clinical-feed/the-lancet-global-health-21-association-of-linezolid-interruption-and-rechallenge-with-clinical-outcomes-in-patients-with-rifampicin-resistant-tuberculosis-in-south-africa-2018-22-an-observational-cohort-study"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "The Lancet Global Health"
source_url: "https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00489-9/fulltext?rss=yes"
doi: "10.1016/S2214-109X(25)00489-9"
published_at: "2026-04-01T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Association of Linezolid Interruption and Rechallenge With Outcomes in Rifampicin-Resistant TB,
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/the-lancet-global-health-21-association-of-linezolid-interruption-and-rechallenge-with-clinical-outcomes-in-patients-with-rifampicin-resistant-tuberculosis-in-south-africa-2018-22-an-observational-cohort-study
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** The Lancet Global Health
- **Source URL:** [Original Journal Publication](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00489-9/fulltext?rss=yes)
- **DOI:** [10.1016/S2214-109X(25)00489-9](https://doi.org/10.1016%2FS2214-109X(25)00489-9)
- **Published At:** 2026-04-01T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Linezolid interruption was common and associated with unfavourable clinical outcomes. Linezolid rechallenge was frequently successful and associated with better clinical outcomes. These findings inform clinical practice and have implications for the management of patients receiving oral, short-course regimens for multidrug-resistant tuberculosis.
## Clinical Analysis & Structured Key Points
The Lancet Global Health published a clinical update in Infectious Disease on 01 Apr 2026. The item focuses on Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018–22: an observational cohort study. Review the original article for the full source wording and details.
## Related Clinical Research

- [Saliva-based nanopore sequencing panel for pharmacogenomic screening in drug-resistant tuberculosis](https://medichelpline.com/clinical-feed/medrxiv-5-nanopore-sequencing-panel-for-saliva-based-host-pharmacogenomic-screening-in.md)
- [Genomic analysis of an optrA-carrying plasmid linked to linezolid resistance in Enterococcus faeca](https://medichelpline.com/clinical-feed/pubmed-42678601.md) (DOI: 10.1007/s10096-026-05657-4)
- [Integrative conjugative element in Streptococcus pyogenes carries a cfr-like gene linked to linezo](https://medichelpline.com/clinical-feed/pubmed-42627159.md) (DOI: 10.1128/msphere.00277-26)
- [Fresh fruit surfaces as reservoirs of multidrug-resistant, biofilm-forming Enterococcus faecalis](https://medichelpline.com/clinical-feed/plos-one-3-fresh-fruit-surface-a-potential-source-for-multidrug-resistant-biofilm-forming.md)
- [Priority use cases for tuberculosis biomarkers and tests across infection, disease, treatment and](https://medichelpline.com/clinical-feed/medrxiv-20-defining-use-cases-for-biomarkers-and-tests-across-tuberculosis-infection.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.